WallStreetZenWallStreetZen

NASDAQ: CYTO
Altamira Therapeutics Ltd Stock

$2.92-0.04 (-1.35%)
Updated Feb 6, 2023
CYTO Price
$2.92
Fair Value Price
$3.10
Market Cap
$2.49M
52 Week Low
$2.70
52 Week High
$43.00
P/E
-0.11x
P/B
0.31x
P/S
5.36x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.35M
Earnings
-$18.89M
Gross Margin
-166.8%
Operating Margin
-1,364.67%
Profit Margin
-1,394.2%
Debt to Equity
1.41
Operating Cash Flow
-$15M
Beta
0.91
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

CYTO Overview

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CYTO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CYTO ($2.92) is undervalued by 5.9% relative to our estimate of its Fair Value price of $3.10 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CYTO ($2.92) is not significantly undervalued (5.9%) relative to our estimate of its Fair Value price of $3.10 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CYTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CYTO due diligence checks available for Premium users.

Be the first to know about important CYTO news, forecast changes, insider trades & much more!

CYTO News

Valuation

CYTO fair value

Fair Value of CYTO stock based on Discounted Cash Flow (DCF)
Price
$2.92
Fair Value
$3.10
Undervalued by
5.90%
CYTO ($2.92) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CYTO ($2.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CYTO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CYTO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.11x
Industry
11.5x
Market
14.99x

CYTO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.31x
Industry
5.06x
CYTO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CYTO's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
CYTO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CYTO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$19.5M
Liabilities
$11.4M
Debt to equity
1.41
CYTO's short-term liabilities ($10.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CYTO's short-term assets ($2.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CYTO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CYTO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
CYTO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

CYTO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CYTO$2.49M-1.35%-0.11x0.31x
ALLR$2.34M-3.80%-0.05x1.62x
SPRC$2.75M-4.30%1.04x1.12x
CFRX$2.75M0.00%-0.05x-0.89x
ENSC$2.04M+0.42%-0.04x-0.33x

Altamira Therapeutics Stock FAQ

What is Altamira Therapeutics's quote symbol?

NASDAQ: CYTO) Altamira Therapeutics trades on the NASDAQ under the ticker symbol CYTO. Altamira Therapeutics stock quotes can also be displayed as NASDAQ: CYTO.

If you're new to stock investing, here's how to buy Altamira Therapeutics stock.

What is the 52 week high and low for Altamira Therapeutics (NASDAQ: CYTO)?

(NASDAQ: CYTO) Altamira Therapeutics's 52-week high was $43.00, and its 52-week low was $2.70. It is currently -93.21% from its 52-week high and 8.15% from its 52-week low.

How much is Altamira Therapeutics stock worth today?

(NASDAQ: CYTO) Altamira Therapeutics currently has 853,213 outstanding shares. With Altamira Therapeutics stock trading at $2.92 per share, the total value of Altamira Therapeutics stock (market capitalization) is $2.49M.

Altamira Therapeutics stock was originally listed at a price of $24,000.00 in Aug 6, 2014. If you had invested in Altamira Therapeutics stock at $24,000.00, your return over the last 8 years would have been -99.99%, for an annualized return of -67.59% (not including any dividends or dividend reinvestments).

How much is Altamira Therapeutics's stock price per share?

(NASDAQ: CYTO) Altamira Therapeutics stock price per share is $2.92 today (as of Feb 6, 2023).

What is Altamira Therapeutics's Market Cap?

(NASDAQ: CYTO) Altamira Therapeutics's market cap is $2.49M, as of Feb 8, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Altamira Therapeutics's market cap is calculated by multiplying CYTO's current stock price of $2.92 by CYTO's total outstanding shares of 853,213.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.